Literature DB >> 15517614

Antagonist anti-human CD40 antibody inhibits germinal center formation in cynomolgus monkeys.

Alex F de Vos1, Marie-José Melief, Debby van Riel, Louis Boon, Marco van Eijk, Mark de Boer, Jon D Laman.   

Abstract

Interactions between CD40 on APC and CD154 (CD40L) expressed by activated CD4(+) T cells are crucially involved in formation and function of germinal centers (GC), but mechanistic insight into these interactions remains limited. Functional studies have mostly been restricted to experimental immunization of young-adult inbred SPF rodents that are often genetically manipulated, while studies in humans disallow in vivo manipulation. Therefore, we asked whether a functional antagonist of CD40 interferes with natural GC formation in adult cynomolgus monkeys (Macaca fascicularis) exposed to the environmental antigens of their conventional housing in captivity. Animals were treated with different doses of a unique chimeric antagonist anti-CD40 mAb (ch5D12) and analyzed 1 week or 7 weeks after last injection. Detailed in situ analysis showed that high-dose anti-CD40 treatment increased the ratio of primary over secondary follicles compared to PBS or low-dose treatment, indicative of impairment of the CG reaction. This impairment was reversible since recovery animals, except those with residual anti-CD40 levels, had normalized ratios. Anti-CD40 treatment was associated with decreased antibody production and increased numbers of apoptotic cells in GC. These data demonstrate that CD40-CD154 interactions are pivotal in physiological GC formation in primates responding to environmental antigens, and they support immunotherapeutic strategies using antagonist anti-CD40.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15517614     DOI: 10.1002/eji.200424973

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  7 in total

Review 1.  Current Treatment, Emerging Translational Therapies, and New Therapeutic Targets for Autoimmune Myasthenia Gravis.

Authors:  Jeffrey T Guptill; Madhu Soni; Matthew N Meriggioli
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

2.  Antibody Engineering & Therapeutics, the annual meeting of The Antibody Society December 7-10, 2015, San Diego, CA, USA.

Authors:  Matthias Pauthner; Jenny Yeung; Chris Ullman; Joost Bakker; Thierry Wurch; Janice M Reichert; Fridtjof Lund-Johansen; Andrew R M Bradbury; Paul J Carter; Joost P M Melis
Journal:  MAbs       Date:  2016       Impact factor: 5.857

3.  CD40 blockade combines with CTLA4Ig and sirolimus to produce mixed chimerism in an MHC-defined rhesus macaque transplant model.

Authors:  A Page; S Srinivasan; K Singh; M Russell; K Hamby; T Deane; S Sen; L Stempora; F Leopardi; A A Price; E Strobert; K A Reimann; A D Kirk; C P Larsen; L S Kean
Journal:  Am J Transplant       Date:  2011-09-19       Impact factor: 8.086

Review 4.  Primate models in organ transplantation.

Authors:  Douglas J Anderson; Allan D Kirk
Journal:  Cold Spring Harb Perspect Med       Date:  2013-09-01       Impact factor: 6.915

5.  Imaging Mass Cytometry and Single-Cell Genomics Reveal Differential Depletion and Repletion of B-Cell Populations Following Ofatumumab Treatment in Cynomolgus Monkeys.

Authors:  Diethilde Theil; Paul Smith; Catherine Huck; Yoann Gilbart; Algirdas Kakarieka; David Leppert; Celine Rauld; Cindy Schmid; Reto Baumgartner; Nathalie Stuber; Francisco Cordoba; Valerie Dubost; Katy Darribat; Magali Jivkov; Wilfried Frieauff; Rainer Kneuer; Markus Stoeckli; Stefan Reinker; Keith Mansfield; José M Carballido; Philippe Couttet; Gisbert Weckbecker
Journal:  Front Immunol       Date:  2019-06-20       Impact factor: 7.561

Review 6.  Molecular basis and therapeutic implications of CD40/CD40L immune checkpoint.

Authors:  TingTing Tang; Xiang Cheng; Billy Truong; LiZhe Sun; XiaoFeng Yang; Hong Wang
Journal:  Pharmacol Ther       Date:  2020-10-20       Impact factor: 12.310

Review 7.  Immune Thrombocytopenia: Recent Advances in Pathogenesis and Treatments.

Authors:  Sylvain Audia; Matthieu Mahévas; Martin Nivet; Sethi Ouandji; Marion Ciudad; Bernard Bonnotte
Journal:  Hemasphere       Date:  2021-06-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.